Table 1.
Participants’ demographic characteristics.
| Participant | Duration of interview | Sex | Declared ethnicity | Age (years) | Time of PD (years) | Time of dance practice (years) | H&Y | Cognition (T-MoCa) | Level of education (years) | Medication LED (mg/day) |
|---|---|---|---|---|---|---|---|---|---|---|
| Lilac | 40 min | F | White | 62 | 7 | 6 | 2 | 19 | Higher Education | Prolopa 400 |
| Turquoise | 72 min | F | White | 56 | 9 | 2 | 3 | 22 | Higher Education | Prolopa 800 |
| Yellow | 33 min | F | White | 76 | 4 | 4 | 3 | 16 | No level | Prolopa 500 |
| Orange | 42 min | F | White | 74 | 6 | 4 | 2.5 | 18 | High School | Prolopa 300 |
| Red | 62 min | F | White | 87 | 8 | 6 | 3 | 15 | No level | Prolopa 400 |
| Navy Blue | 47 min | M | White | 67 | 2 | 2 | 2 | 22 | High School | Prolopa 600 |
| Mustard | 42 min | M | White | 70 | 5 | 3 | 1 | 21 | Higher Education | Prolopa 200 |
| Light Green | 30 min | F | Black | 67 | 3 | 3 | 3 | 15 | No level | Prolopa 300 |
| Brown | 29 min | M | White | 67 | 3 | 2 | 2.5 | 16 | High School | Prolopa 400 |
| Violet | 32 min | F | White | 85 | 24 | 3 | 1.5 | 21 | High School | Prolopa 800 |
| Burgundy | 40 min | F | Black | 68 | 14 | 6 | 3 | 18 | High School | Cardiodopa 1,200 |
| Dark Green | 46 min | F | White | 66 | 6 | 3 | 3 | 15 | No level | Prolopa 800 |
| Pink | 38 min | F | White | 67 | 6 | 3 | 3 | 19 | High School | Prolopa 800 |
| Gray | 42 min | M | White | 83 | 6 | 3 | 3 | 16 | Elementary School | Prolopa 300 |
| Mean | 42.5 | NA | NA | 71.1 | 7.4 | 3.6 | 2.6 | 18.1 | NA | 607.1 |
| SD | 11.9 | NA | NA | 8.9 | 5.7 | 1.5 | 0.7 | 2.6 | NA | 239.9 |
| % | NA | 64% F 36% M |
86% W 14% B |
NA | NA | NA | NA | NA | 21% HE 43% HS 7% ES 29% NL |
7% LC 93% P |
Parkinson’s disease (PD); minutes (min); Hoehn & Yahr (H&Y) scale; Telephone Montreal Cognitive Assessment Test (T-MoCA); Standard deviation (SD); Not applicable (NA); Female (F); Male (M); White (W); Black (B); Higher Education (HE); High School (HS); Elementary School (ES); No level (NL); Levodopa-Carbidopa (LB); Prolopa (P). Levodopa equivalent daily dose (LED) (Tomlinson et al., 2010).